Rabinovich Peter M, Komarovskaya Marina E, Ye Zhi-Jia, Imai Chihaya, Campana Dario, Bahceci Erkut, Weissman Sherman M
Department of Genetics, Yale University School of Medicine, New Haven, CT 06520, and Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Hum Gene Ther. 2006 Oct;17(10):1027-35. doi: 10.1089/hum.2006.17.1027.
Transfection of human cells with DNA in biomedical applications carries the risk of insertional mutagenesis. Transfection with mRNA avoids this problem; however, in vitro production of mRNA, based on preliminary DNA template cloning in special vectors, is a laborious and time-consuming procedure. We report an efficient vectorfree method of mRNA production from polymerase chain reaction-generated DNA templates. For all cell types tested mRNA was transfected more readily than DNA, and its expression was highly uniform in cell populations. Even cell types relatively resistant to transfection with DNA could express transfected mRNA well. The level of mRNA expression could be controlled over a wide range by changing the amount of input RNA. Cells could be efficiently and simultaneously loaded with several different transcripts. To test a potential clinical application of this method, we transfected human T lymphocytes with mRNA encoding a chimeric immune receptor directed against CD19, a surface antigen widely expressed in leukemia and lymphoma. The transfected mRNA conferred powerful cytotoxicity to T cells against CD19+ targets from the same donor. These results demonstrate that this method can be applied to generate autologous T lymphocytes directed toward malignant cells.
在生物医学应用中,用DNA转染人类细胞存在插入诱变的风险。用mRNA转染可避免此问题;然而,基于在特殊载体中初步克隆DNA模板的mRNA体外生产是一个费力且耗时的过程。我们报告了一种从聚合酶链反应生成的DNA模板高效生产无载体mRNA的方法。对于所有测试的细胞类型,mRNA比DNA更容易转染,并且其在细胞群体中的表达高度一致。即使是对DNA转染相对抗性的细胞类型也能很好地表达转染的mRNA。通过改变输入RNA的量,可以在很宽的范围内控制mRNA的表达水平。细胞可以高效且同时加载几种不同的转录本。为了测试该方法的潜在临床应用,我们用编码针对CD19(一种在白血病和淋巴瘤中广泛表达的表面抗原)的嵌合免疫受体的mRNA转染人T淋巴细胞。转染的mRNA赋予T细胞对来自同一供体的CD19+靶标的强大细胞毒性。这些结果表明,该方法可用于产生针对恶性细胞的自体T淋巴细胞。